Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.
David B AntcliffeShalini SanthakumaranRobert M L OrmeJosie K WardFarah Al-BeidhKieran O'DeaGavin D PerkinsMervyn SingerDaniel F McAuleyAlexina J MasonMary CrossDeborah AshbyAnthony C GordonPublished in: Intensive care medicine (2019)
Adding levosimendan to standard care in septic shock was not associated with less severe organ dysfunction nor lower mortality in patients with biochemical evidence of cardiac dysfunction.